With the aging of the age and population aging process intensified, the demand for drugs for musculoskeletal diseases continues to increase, in 2023 in China's three major terminals in six markets proprietary drugs for musculoskeletal system diseases market exceeded 40 billion yuan.
In recent years, the domestic new drugs in the health insurance to help take off, Kang Yuan Pharmaceutical's tendon and bone pain gel continued to rise, the potential is promising.
At present, in the terminal of public medical institutions and urban brick-and-mortar pharmacies, exclusive products are still the main sales force, Yunnan Baiyao, Antelope Pharmaceuticals, Qizheng Group, China Resources Sanjiu and other Chinese medicine star enterprises have a number of over 100 million products to dominate the market.
Previous: The $400bn pCm market takes off!
Next: 没有了